Crafting an international database for retinopathy of prematurity
Intercontinental collaboration is key to unlocking ROP in our lifetime
A new home treatment for amblyopia
Binocular eye tracking could serve as alternative to patching and provide visual acuity gains with heightened adherence rates
US FDA approves continuous delivery ranibizumab treatment (Susvimo, Genentech) for diabetic macular oedema
Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States
Nuance Audio hearing aid glasses receive concurrent CE Mark and FDA approval
The hearing aid glasses from EssilorLuxottica received CE marking under the Medical Devices Regulation of the EMA
Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy
OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication
European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars
Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration
Viralgen and Axovia Therapeutics enter partnership, target retinal dystrophy in Bardet-Biedl Syndrome
The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025
SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel
The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections
Study identifies associations between childhood unilateral amblyopia and cardiometabolic disorders
Investigators examined the connection between amblyopia, components of the metabolic syndrome and individual cardiometabolic diseases
Hoya Vision Care expands MiYOSMART spectacle lens power range to offer broader range of negative and cylindrical powers
The extension includes lenses that range from minus power of -13.00 diopters to cylindrical power up to 4.00 diopters
Apellis Pharmaceuticals receives Australian approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy
The approval of Syfovre makes it the first and only approved treatment for GA in Australia.
Deafblind UK and Birmingham City University announce education and research centre
The centre will facilitate research and access to resources for the 450,000 residents of the UK who are affected by sight and hearing loss
MACUSTAR receives additional EMA support for AMD clinical study
The scientific outputs from MACUSTAR’s study could impact more than 200 million patients with AMD globally
HELIOS trial 1-year results assess implant for treatment of non-proliferative diabetic retinopathy
Diana V. Do, MD, spoke on behalf of the HELIOS investigators at the Hawaiian Eye and Retina 2025 Meeting, in Kauai, HI
Study describes ‘triangle sign’ as key to differentiating total choroidal detachments and suprachoroidal hemorrhages
Ultrasounds reveal the distinct feature within the vitreous anterior, a promising diagnostic indicator for ocular pathologies
Arctic Vision receives approval in Australia and Singapore for uveitic macular oedema treatment ARVN001
ARCATUS or ARVN001 was developed by Clearside Biomedical and commercialised in the Asia-Pacific region by Arctic Vision
NeurEYE research team leads AI-supported dementia detection programme with Scottish optometrists
Predictive software will use retinal imaging to identify patient risk for Alzheimer and other neurodegenerative diseases
Home storage of anti-VEGF agents presents risk of temperature changes
The study findings suggest that patients should be educated about adherence to cold storage guidelines
BLINK2 study results demonstrate myopia control outcomes following multifocal contact lens discontinuation
Participants wore high-add multifocal soft contact lenses for 2 years and single-vision lenses during the third year to determine if rebound occurred
iCare announces updated MAIA TrueColor Microperimetry System
The updated device is designed to meet market diagnostic needs, including within geographic atrophy research
Artificial intelligence supports screening more paediatric patients at lower cost
Autonomous, AI-based screening consistently resulted in more patients screened with greater cost savings, investigators said
Plant pathogen Macrophomina phaseolina may be emerging cause of ocular infection in humans
A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment
PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy
RhyGaze announces $86 million in Series A financing for optogenetic vision restoration therapy candidate
The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial
US FDA approves Zeiss MEL 90 excimer laser for myopia, hyperopia and mixed astigmatism
The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software
Teva partners with Klinge Biopharma for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)
The commercialisation agreement for the biosimilar to aflibercept (Eylea) covers Israel and major parts of Europe, excluding Italy
Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union
The launch follows a CE Mark received in late 2024
Study explores possible applications of retinal imaging in schizophrenia detection
The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases
Retinopathy of prematurity study demonstrates noninferiority of combination microdrops compared to standard mydriatics
The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening
ViGeneron receives rare paediatric disease designation from US FDA for retinitis pigmentosa gene therapy candidate VG901
ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial
